Investigating a genetic polymorphism in Egyptian patients with psoriatic arthritis
Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient and Its Relation With Response to Methotrexate
This study is testing if a specific gene variation affects how Egyptian patients with psoriatic arthritis respond to treatment with methotrexate compared to a placebo.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Sponsor | South Valley University Academic / other |
| Drugs / interventions | methotrexate |
| Locations | 1 site (Qina) |
| Trial ID | NCT06870500 on ClinicalTrials.gov |
What this trial studies
This study examines the Card14 gene polymorphism (rs34367357) in Egyptian patients suffering from psoriatic arthritis, a chronic inflammatory condition associated with psoriasis. It aims to understand the genetic factors contributing to the disease's severity and response to treatment. Participants will receive either methotrexate or a placebo, with their responses monitored to assess the effectiveness of the treatment. The study seeks to clarify the role of genetic predisposition in the management of psoriatic arthritis.
Who should consider this trial
Good fit: Ideal candidates are Egyptian adults aged 18 and older with moderate to severe psoriasis and possible psoriatic arthritis.
Not a fit: Patients with other autoimmune conditions, pregnancy, or those currently on immunosuppressive therapies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment strategies for patients with psoriatic arthritis based on their genetic profiles.
How similar studies have performed: While the specific genetic focus may be novel, studies on genetic polymorphisms in autoimmune diseases have shown varying degrees of success in understanding disease mechanisms and treatment responses.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18 years and above. * Patients having psoriasis diagnosed clinically and who have a severity grade of moderate to severe, defined as a Psoriasis Area and Severity Index (PASI) score from 5- 10 % of body surface area, and involvement of greater than 10% of the body surface area (BSA) with or without psoriatic arthritis Exclusion Criteria: * Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus). * Pregnancy and lactation. * Patients currently undergoing immunosuppressive or systemic therapies. * Patients with known genetic disorders affect immune system function. * Patients with liver or kidney impairment. * Patients with allergy or contraindication to methotrexate. * Patients with active or uncontrolled infections, including chronic infections like tuberculosis.
Where this trial is running
Qina
- Qina University hospital, South Valley University Hospital — Qina, Egypt (Recruiting)
Study contacts
- Study coordinator: Marwa Naguib Ahmed, MSc
- Email: omarahmed331166@yahoo.com
- Phone: +201099283315
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.